Angiocrine Bioscience
PrivateLast Round
VC Round
Sep 4, 2025
Total Funding Raised
$45.83M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Angiocrine Bioscience is a biotechnology company that develops a curative cellular therapies platform aimed at treating conditions in regenerative medicine and hematopoietic stem cell gene therapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Angiocrine Bioscience Comparables
Compare Angiocrine Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gamida Cell Ltd. | 76% | |
| Ossium Health | 71% | |
| Pluri | 69% |
Angiocrine Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 4, 2025 | ||||
| Grant | Dec 19, 2022 | ||||
| Grant | Dec 15, 2022 | ||||
| Series B | Mar 29, 2022 | ||||
| Grant | Aug 24, 2017 | ||||
Grant | Feb 23, 2017 |
Angiocrine Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Good Growth Capital | Series B |
| California Institute for Regenerative Medicine | Grant |
| Cobro Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 416% MoM, from 462 to 2.4K.
- Aug 21, 2015
$2.1M round completed.
Angiocrine Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Angiocrine Bioscience's valuation, stock price, and market status.
Is Angiocrine Bioscience a public or private company?
Angiocrine Bioscience is a private company.
What is the current stock price of Angiocrine Bioscience?
Angiocrine Bioscience is a private company with no public stock price. No recent secondary market data is available.
How much is Angiocrine Bioscience worth (valuation)?
Valuation information for Angiocrine Bioscience is not publicly available.
Can I buy Angiocrine Bioscience stock?
Angiocrine Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Angiocrine Bioscience's last funding round?
Angiocrine Bioscience's most recent funding round was VC Round on September 4, 2025.
Who are the main investors in Angiocrine Bioscience?
Key investors in Angiocrine Bioscience include California Institute for Regenerative Medicine, Cobro Ventures.
Will Angiocrine Bioscience IPO soon?
No public IPO plans have been announced for Angiocrine Bioscience.
How can I track Angiocrine Bioscience secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Angiocrine Bioscience's secondary market activity and sign up for updates.